
The slide to be stained for pan-cytokeratin (pan-CK) comprised:
1: liver,
2:
lung
squamous cell carcinoma, 3:
lung
small cell
lung
carcinoma (SCLC), 4:
appendix,
5:
adrenal
gland,
6:
testicular
seminoma, 7:
parotid
gland.
Criteria for assessing a pan-CK staining as
optimal included: A strong and distinct staining of the large
majority of epithelial cells in the appendix, parotid gland, and
biliary tract of the liver, while most hepatocytes should reveal at
least a moderate membranous staining and the adrenal gland at
least
a focal
staining. In most tumour cells of the squamous cell carcinoma and
the small cell lung carcinoma, a strong and distinct staining should
be seen, dot-like in the latter The seminoma should focally be
strongly labelled. A slight overstaining of cells with many epitopes
was accepted (this is almost inevitable in order to avoid false
negative stainings).
72 laboratories submitted stainings. At the
assesment 15 achieved optimal staining
(21 %), 23 good (32 %), 24 borderline (33 %) and
10 (14%) poor staining.
The following
pan-CK markers were used:
|
MNF116
|
DakoCytomation (14) |
|
KL1
|
Immunotech (8), Serotec (1), Biomeda (1) |
| AE1/AE3
|
DakoCytomation (30), Zymed (2),
Boehringer Mannheim (4), Biogenex (1), Biomeda (1) |
| AE1/AE3 + PCK26 |
Ventana (3) |
|
AE1/AE3 + 5D3 |
BioCare (1) |
|
NCL-Pan-CK |
Novocastra (4) |
|
Pan-CK Ab2 |
NeoMarkers (1) |
|
Polyclonal Z0622 |
DakoCytomation (1) |
Optimal stainings were
obtained with
the clones AE1/AE3 (DakoCytomation), AE1/AE3 + 5D3 (BioCare)
and KL1 (Serotec and Immunotech). When using these, all protocols were based on HIER
with
Tris-EDTA/EGTA pH
9 (14 labs.) or EDTA pH 8 (1 lab.) as the heating buffer.
mAb clone AE1/AE3 with proteolytic pre-treatment
(Proteinase K, Pronase E, Trypsin or equivalent) gave inferior
results with a consistent negative reaction in cells with scarce
amounts of low molecular weight cytokeratins type 8 (i.e.,
hepatocytes and a subset of acinar cells of the parotid gland).
On the other hand the majority of protocols based on proteolytic pre-treatment
were able to detect CK in the SCLC and the squamous cell
carcinoma.
The cocktail AE1/AE3 + PCK26 (3 labs) was only
used with proteolytic pre-treatment. Thus, it was not possible to
evaluate the potential of this marker with HIER.
Using mAb clone MNF116 (14 labs.) in combination
with proteolytic pre-treatment, a good (but not optimal) result
could be obtained in this assessment.
The most frequent causes of insufficient
stainings were:
-Inappropriate
retrieval (Proteolysis for AE1/AE3)
-Too weak HIER (short heating time and/use of
citrate pH 6)
-Too low concentration of primary antibody
-Inappropriate choice of pan-CK antibody
-Use of HIER for mAb MNF116
|